NEW YORK (GenomeWeb) – Interleukin Genetics today announced it has received conditional approval from New York State to offer its genetic test for periodontal disease.
Also, the firm's VP of Development and Clinical Operations Lynn Doucette-Stamm has received a certification for qualification from the state as a lab director for genetic testing. She heads the Interleukin Clinical Operations and Research and Development teams.
As a result of the conditional approval from the New York State Department of Health, Interleukin can now offer its PerioPredict test in all 50 states in the US.
The test is conducted during a routine dental exam or cleaning and measures variations in genes for Interleukin-1, a mediator of inflammation, to identify individuals at increased risk for moderate to severe periodontal disease. Interleukin has been processing PerioPredict in its CLIA-certified lab in Waltham, Mass., since January.